▶ MATRIXYL-3000 · SUBTOPIC · MECHANISM
MATRIXYL-3000 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Two-peptide blend: palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR). Both are matrikine peptides (extracellular-matrix-derived signaling fragments) that drive fibroblast collagen synthesis, elastin synthesis, and glycosaminoglycan production. Topical-cosmetic application.
PHARMACOKINETIC HALF-LIFE
Reported half-life for MATRIXYL-3000: n/a · topical · no systemic exposure. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
MATRIXYL-3000 is a defined sequence: Palmitoyl-Gly-His-Lys (pal-GHK) + Palmitoyl-Gly-Gln-Pro-Arg (pal-GQPR). Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
MATRIXYL-3000 is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Cosmetic dermatology peptides act topically on dermal fibroblasts, the neuromuscular junction, or epidermal melanocytes to drive measurable improvements in fine lines, wrinkle depth, skin tone, and barrier function. Argireline (acetyl hexapeptide-8) is a SNAP-25 fragment that inhibits SNARE-complex-mediated acetylcholine release at the neuromuscular junction. Matrixyl-3000 combines two matrikine peptides (palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7) that signal collagen and glycosaminoglycan synthesis. SNAP-8 (acetyl octapeptide-3) extends the Argireline sequence by two residues for stronger SNARE-complex inhibition.
The dermal extracellular matrix comprises collagen (primarily type I and III), elastin, and glycosaminoglycans (hyaluronic acid, dermatan sulfate). Age-related skin changes reflect declining synthesis and increased degradation of these components. GHK-Cu is the most-studied research peptide for direct transcriptional induction of dermal-matrix synthesis.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Sederma in-vitro fibroblast data describes upregulation of collagen I, IV, VII and fibronectin.
Robinson 2005 reported wrinkle improvement with palmitoyl pentapeptide topical formulation.
Multiple small cosmetic trials. Limited large-scale RCT evidence.
MECHANISM Q+A
▶ What is Matrixyl-3000?
Matrixyl-3000 is a two-peptide cosmetic blend developed by Sederma. The components are palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR), both matrikine peptides (extracellular-matrix-derived signaling fragments). The blend drives fibroblast collagen and glycosaminoglycan synthesis.
▶ Matrixyl-3000 vs Argireline · what's the difference?
Different mechanisms targeting different wrinkle types. Argireline blocks SNARE-complex assembly at the neuromuscular junction, reducing dynamic expression-line wrinkles. Matrixyl-3000 stimulates dermal collagen and GAG synthesis, addressing static wrinkles from extracellular matrix loss. The two are complementary; many cosmetic formulations combine them.
▶ Matrixyl-3000 vs GHK-Cu · which is better?
Both target collagen synthesis but through different mechanisms. GHK-Cu (Gly-His-Lys + Cu²⁺) is the original copper-peptide first identified in the 1970s with documented collagen and elastin synthesis induction. Matrixyl-3000 uses two palmitoylated matrikine peptides for similar but distinct signaling. Both have evidence for wrinkle reduction; GHK-Cu has the longer evidence base.
▶ How does Matrixyl-3000 work?
The matrikine peptides mimic small fragments released during extracellular matrix turnover. These fragments signal to fibroblasts to upregulate new collagen (I, IV, VII), elastin, and glycosaminoglycan synthesis · the same response a fibroblast produces during normal wound healing. The palmitoyl moiety enables transdermal penetration.
CITED LITERATURE
- Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci 2000. link
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25